APA (7th ed.) Citation

Krauter, J., Fiedler, W., Schlenk, R. F., Paschka, P., Thol, F., Lübbert, M., . . . Heuser, M. (2018). Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). British journal of haematology, 183(2), . https://doi.org/10.1111/bjh.15546

Chicago Style (17th ed.) Citation

Krauter, Jürgen, et al. "Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Newly Diagnosed Patients with Acute Myeloid Leukaemia and High Risk for Induction Failure (AMLSG 17-10 CIARA Trial)." British Journal of Haematology 183, no. 2 (2018). https://doi.org/10.1111/bjh.15546.

MLA (9th ed.) Citation

Krauter, Jürgen, et al. "Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Newly Diagnosed Patients with Acute Myeloid Leukaemia and High Risk for Induction Failure (AMLSG 17-10 CIARA Trial)." British Journal of Haematology, vol. 183, no. 2, 2018, https://doi.org/10.1111/bjh.15546.